WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

NCT02508246 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Cisplatin
DRUG: Docetaxel
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
PROCEDURE: Therapeutic Conventional Surgery
DRUG: WEE1 Inhibitor AZD1775

Sponsor

University of Washington

Collaborators

[object Object]